首页|期刊导航|癌症生物学与医学（英文版）|CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy

CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy

Hui Luo Tongjuan Li Fankai Meng Zhenya Hong Yang Cao Gaoxiang Wang Liang Huang Xiaoxi Zhou

癌症生物学与医学（英文版）2025，Vol.22Issue(5)：496-501,6.

癌症生物学与医学（英文版）2025，Vol.22Issue(5)：496-501,6.DOI:10.20892/j.issn.2095-3941.2024.0626

CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy

Hui Luo ¹Tongjuan Li ¹Fankai Meng ¹Zhenya Hong ¹Yang Cao ¹Gaoxiang Wang ¹Liang Huang ¹Xiaoxi Zhou¹

作者信息

1. Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China||Immunotherapy Research Center for Hematologic Diseases of Hubei Province,Wuhan 430030,China
折叠

摘要

引用本文复制引用

Hui Luo,Tongjuan Li,Fankai Meng,Zhenya Hong,Yang Cao,Gaoxiang Wang,Liang Huang,Xiaoxi Zhou..CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy[J].癌症生物学与医学（英文版）,2025,22(5):496-501,6.

基金项目

This work was supported by funding from the National Natural Science Foundation of China(Grant No.82170167 to Xiaoxi Zhou and Grant No.82300226 to Hui Luo). （Grant No.82170167 to Xiaoxi Zhou and Grant No.82300226 to Hui Luo）

癌症生物学与医学（英文版）

ISSN：2095-3941

访问量0

下载量0

段落导航